APMD
NASD Apnimed, Inc.$21.51 ↑ +0.00 (+0.00%) Trading Up from the previous close of $21.51, $1.22 below the day’s high of $22.73
- YTD change
- -13.96%
- vs 20-day SMA
- -15.22%
- vs 200-day SMA
- N/A
Price ranges
Price & Performance
-3.49 (-13.96%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 39.0% away from all-time highs of $35.29
- APMD is down 14% since the beginning of the year
- APMD is down 14% over the past 12 months
- APMD is down 23% over the past 1 month
- 2% of all APMD investors are betting against APMD
APMD reads not so good: the 12-month move is -14.0%.
- Previous minute
- +$0.01
- Last hour
- -$0.04
- Last 5 days
- -0.55%
- vs 8-day SMA
- -4.79%
No alerts for APMD in the last day.
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Apnimed, Inc. operates as a clinical-stage company. It engages in the discovery, development, and commercialization of oral therapies for sleep-related breathing diseases. The company was founded by Lawrence G. Miller, Barry Wohl and Luigi Taranto Montemurro in 2017 and is headquartered in Cambridge, MA.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.